These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9593132)

  • 1. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
    Eliopoulos GM; Wennersten CB; Gold HS; Schülin T; Souli M; Farris MG; Cerwinka S; Nadler HL; Dowzicky M; Talbot GH; Moellering RC
    Antimicrob Agents Chemother; 1998 May; 42(5):1088-92. PubMed ID: 9593132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium.
    Bonilla HF; Perri MB; Kauffman CA; Zervos MJ
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):127-31. PubMed ID: 8902408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
    Eliopoulos GM; Wennersten CB
    Antimicrob Agents Chemother; 2002 May; 46(5):1319-24. PubMed ID: 11959562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens.
    McDonald LC; Rossiter S; Mackinson C; Wang YY; Johnson S; Sullivan M; Sokolow R; DeBess E; Gilbert L; Benson JA; Hill B; Angulo FJ
    N Engl J Med; 2001 Oct; 345(16):1155-60. PubMed ID: 11642231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
    Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
    Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
    Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
    J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China.
    Wang S; Guo Y; Lv J; Qi X; Li D; Chen Z; Zhang X; Wang L; Yu F
    BMC Microbiol; 2016 Oct; 16(1):246. PubMed ID: 27769188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V; Fernandes F
    Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.
    Bozdogan B; Leclercq R
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2720-5. PubMed ID: 10543753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
    Aeschlimann JR; Zervos MJ; Rybak MJ
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
    Matsumura SO; Louie L; Louie M; Simor AE
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2776-9. PubMed ID: 10543762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
    Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
    Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibilities of clinical isolates of vancomycin-resistant enterococci in Taiwan.
    Hsueh PR; Wu JJ; Lu JJ; Teng LJ; Luh KT
    J Formos Med Assoc; 1999 Jan; 98(1):45-8. PubMed ID: 10063273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.